Immunotherapy: Recent Advances and Its Future as a Neoadjuvant, Adjuvant, and Primary Treatment in Colorectal Cancer

卷:12

Review

关键词: TUMOR MUTATIONAL BURDEN;    T-CELL THERAPY;    MICROSATELLITE INSTABILITY;    DENDRITIC CELLS;    SOLID TUMORS;    ANTIBODY;    PD-L1;    BLOCKADE;    CRITERIA;    EXPRESSION;   

DOI  :  10.3390/cells12020258

来源: SCIE

【 摘 要 】

Immunotherapy in colorectal cancer (CRC) has made great strides within the past decade. Immune checkpoint inhibitors are a class of immunotherapy and have been shown to greatly improve patient outcomes in mismatch repair-deficient (dMMR) CRC. Now, they are part of the standard of care for this subset of CRC. Because of this, there has been a growing interest in the efficacy and timing of immunotherapy for other subsets of CRC, including locally advanced, metastatic, and microsatellite stable (MSS). In this review, we aim to examine the three main classes of immunotherapy for CRC-immune checkpoint inhibitors (ICIs), adoptive cell transfer therapy (ACT), and tumor vaccines-and discuss the most recent advances and future directions for each.